Eur Neuropsychopharmacol
May 20, 2016
Anna Rickli, Olivier D. Moning, Marius C. Hoener et al.
374 citations
Novel psychoactive tryptamines (DiPT, 4-OH-DiPT, 4-OH-MET, 5-MeO-AMT, and 5-MeO-MiPT) interact with serotonin 5-HT2A receptors as partial or full agonists, but with lower binding affinity than LSD. Their binding affinity correlates with reported psychoactive doses in humans. Several of these tryptamines, like psilocin and DMT, also interact with the serotonin transporter and partially with the norepinephrine transporter, similar to MDMA, whereas LSD does not. LSD, but not the tryptamines, interacts with adrenergic and dopaminergic receptors. The receptor interaction profiles suggest these tryptamines produce hallucinogenic effects similar to classic serotonergic hallucinogens along with MDMA-like psychoactive properties.
Eur Neuropsychopharmacol
April 12, 2016
Mendel Kaelen, Leor Roseman, Joshua Kahan et al.
143 citations
Psychedelic drugs like LSD are being re-examined for therapeutic use, often combined with music during psychotherapy. In a placebo-controlled fMRI study with 12 healthy volunteers, researchers investigated how LSD and music together affect mental imagery. They found that the combination of LSD and music increased functional connectivity and information flow from the parahippocampal cortex to the visual cortex. This enhanced connectivity correlated with stronger eyes-closed visual imagery, including autobiographical imagery. The findings suggest a neural mechanism by which music and LSD synergistically enhance subjective experiences that may be valuable in therapeutic settings.
Eur Neuropsychopharmacol
November 7, 2025
Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al.
12 citations
A living systematic review with meta-analysis examined the efficacy, safety, and all-cause discontinuation of serotonergic psychedelics and MDMA for treating mental disorders. The review found that these substances show promise in reducing symptoms of conditions such as depression, anxiety, and post-traumatic stress disorder, with some evidence supporting their therapeutic potential. However, the authors note that the overall quality of evidence is limited by small sample sizes, short follow-up periods, and methodological concerns. Safety profiles varied, with most adverse events being mild to moderate, though serious adverse events were reported in some studies. The review emphasizes the need for larger, more rigorous trials to confirm these findings.
Eur Neuropsychopharmacol
June 5, 2026
Andreas Reif, A. Elif Anıl Yağcıoğlu, Istvan Bitter et al.
No Summary
Eur Neuropsychopharmacol
December 3, 2025
Integrating psychedelic therapies into European healthcare requires not only European Medicines Agency (EMA) approval for safety, efficacy, and quality, but also positive Health Technology Assessment (HTA) evaluations from each member state, which assess added therapeutic value, cost-effectiveness, and societal impact. HTA bodies like the UK's NICE, Germany's IQWiG, and France's HAS often demand active comparator studies rather than placebo controls to demonstrate advantage over existing care—a major hurdle since such trials for psychedelic-assisted therapies are almost absent. The combination of psychedelics with psychotherapy further complicates evaluations, as few frameworks assess combination therapies. A standardized European HTA approach could promote equitable access across countries.